Open AccessTargeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
Author(s) -
Masaoki Ito,
Carles Codony,
Niki Karachaliou,
Rafael Rosell
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.08.25
Subject(s) - auranofin , cancer research , epidermal growth factor receptor , medicine , lung cancer , protein kinase b , tyrosine kinase , signal transduction , cancer , biology , oncology , immunology , receptor , microbiology and biotechnology , rheumatoid arthritis
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). However, universal progression is observed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom